Sciencast Management LP lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 37.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,668 shares of the medical equipment provider’s stock after selling 5,090 shares during the quarter. Sciencast Management LP’s holdings in Hologic were worth $335,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Hologic during the 1st quarter valued at about $146,000. Synovus Financial Corp acquired a new position in Hologic during the 1st quarter valued at about $164,000. Homrich & Berg acquired a new position in Hologic during the 4th quarter valued at about $219,000. IBM Retirement Fund acquired a new position in Hologic during the 1st quarter valued at about $227,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Hologic during the 4th quarter valued at about $235,000. 93.33% of the stock is currently owned by hedge funds and other institutional investors.
Get Hologic alerts:In related news, insider Peter J. Valenti III sold 10,107 shares of the stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total transaction of $389,321.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Karleen Marie Oberton sold 12,196 shares of the stock in a transaction that occurred on Wednesday, May 2nd. The stock was sold at an average price of $40.00, for a total value of $487,840.00. Following the sale, the vice president now directly owns 13,825 shares of the company’s stock, valued at $553,000. The disclosure for this sale can be found here. 0.88% of the stock is currently owned by corporate insiders.
Shares of NASDAQ:HOLX opened at $40.24 on Tuesday. The company has a market capitalization of $11.04 billion, a P/E ratio of 19.82, a PEG ratio of 1.91 and a beta of 0.86. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.98 and a current ratio of 1.26. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $46.80.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The business had revenue of $789.30 million for the quarter, compared to the consensus estimate of $781.23 million. During the same period last year, the company posted $0.50 EPS. Hologic’s revenue for the quarter was up 10.3% on a year-over-year basis. analysts forecast that Hologic, Inc. will post 2.23 EPS for the current fiscal year.
A number of research firms have issued reports on HOLX. Leerink Swann downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the company from $48.00 to $41.00 in a research report on Thursday, May 3rd. BTIG Research restated a “buy” rating and set a $44.00 target price on shares of Hologic in a research report on Sunday, May 6th. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research report on Monday, April 30th. BidaskClub upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research report on Friday, April 27th. Finally, TheStreet downgraded shares of Hologic from a “b-” rating to a “c-” rating in a research report on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company’s stock. Hologic currently has a consensus rating of “Hold” and an average target price of $44.87.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
No comments:
Post a Comment